


[www.isad.org](http://www.isad.org)



**MELBOURNE** 15th Georg RAJKA  
International Symposium on Atopic Dermatitis  
24-26 OCT 2025 AUSTRALIA  
*Memory, History and Retelling*

# Our Society's spirit



Georg Rajka 1925-2013

Keep

- Keep the original G Rajka spirit, independent minded

Do not limit

- Do not limit the field to dermatology


Cover

- Cover all aspects of AD from basic to clinical research

Think

- Think global, not only western style






2025:  
G Rajka  
centennial  
birth  
anniversary

# ISAD: major deliverables since Doha 2024

- Misinformation in AD: influence of social media: *Spring Live Global Virtual Symposium, Friday April 4th, 2025*  
Taïeb A. Topical Steroid Withdrawal: The Challenging Transition from Patient Self-Diagnosis on Social Media to Medical Science and Care. *Acta Derm Venereol.* 2025
- Monthly newsletter including and Editorial and PubMed picks
- Major publication
  - Minić-Pantić D, Abela B, Lehtimäki J, Zink A, Jensen-Jarolim E, Fettelschoss-Gabriel A, Traidl-Hoffmann C, Ring J, Schmid-Grendelmeir P, Prélaud P, Taïeb A. Examining Atopic Dermatitis Through the One Health Concept Lens. *Allergy.* 2025
- Open WHO Course AD on Black Skin translations (French, Portuguese, Spanish)
- Application for low-cost moisturizers successfully included in 2025 EML Core List
- Taïeb A, Loden M, Schmid-Grendelmeir P. Evidence-based moisturizer selection for atopic dermatitis. *JAAD Int.* 2025 May 17;21:28-29. doi: 10.1016/j.jdin.2025.02.007. PMID: 40585943; PMCID: PMC12205554.

[www.isad.org](http://www.isad.org)





# WHO Essential Medicines List Successful Application 2025: Moisturizers for AD

## Step 1: Conditional criteria:


**Systematic literature search**  
([section 8](#))

**Pathophysiology:**  
barrier function, pH, risk of  
Irritation ([section 5](#))


**Manufacturing:**  
pH stabilization, shelf life  
([annex 2](#))

**Production costs**  
([section 10](#))

## Step 2: Operational criteria



A- Authorization of product: systematic search of  
WHO-listed Regulatory Authorities' databases of  
medicinal drug products



B-evidence of clinical efficacy (dryness in AD)  
+ transparent data on the impact on skin  
barrier function



C-Expert Writing Group Discussion for final choice



Criteria of choice for inclusion in EML and EMLc



## WHO Essential Medicines List Successful Application 2025: Moisturizers for AD

*Taïeb A, Loden M, Schmid-Grendelmeir P. Evidence-based moisturizer selection for atopic dermatitis. JAAD Int. 2025 May 17;21:28-29.*

**ISAD-WHO APPLICATION**

**Approvals by Medical  
Authorities**

**Systematic Reviews**  
Grading of Study Quality

**Randomised Double-Blind**  
Studies vs untreated/ reference

***In vitro*, animals,  
anecdotes, open studies**

# WHO-ISAD pre-meeting



- Group photo

# WHO-ISAD pre-meeting

- **Feasibility of the Treat-to-Target (T2T) Strategy in Atopic Dermatitis (AD)**
  - T2T Strategy in AD: Benchmarking with Other Specialties
  - Rheumatology, Pulmonology, Adults vs Children,
  - AD patient's voices as the main anchor
- **Update on the ISAD-WHO Roadmap for AD in Low- and Middle-Income Countries (LMICs)**
  - New project in Côte d'Ivoire: MDA scabies/atopic dermatitis
  - How to implement the EML moisturizer procurement and availability
  - Access to innovative drugs in LMICs
  - Collaboration to Skin Disease WHA resolution implementation

[www.isad.org](http://www.isad.org)



**MELBOURNE** 15th Georg RAJKA  
International Symposium on Atopic Dermatitis  
24-26 OCT 2025 AUSTRALIA  
*Memory, History and Retelling*